SLNO
Soleno Therapeutics Inc

8,232
Mkt Cap
$2.26B
Volume
1.21M
52W High
$90.32
52W Low
$37.95
PE Ratio
-22.87
SLNO Fundamentals
Price
$39.58
Prev Close
$42.12
Open
$42.14
50D MA
$46.31
Beta
0.80
Avg. Volume
1.75M
EPS (Annual)
-$4.38
P/B
4.57
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Soleno Therapeutics (NASDAQ:SLNO) Lowered to "Hold" Rating by Zacks Research
Zacks Research cut Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome
RARE resubmits FDA filing for UX111 after CRL, adding long-term neurologic and biomarker data, with a Q3 2026 decision in sight.
Zacks·3d ago
News Placeholder
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·3d ago
News Placeholder
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week Low - Should You Sell?
Soleno Therapeutics (NASDAQ:SLNO) Sets New 52-Week Low - What's Next...
MarketBeat·6d ago
News Placeholder
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
Zacks·6d ago
News Placeholder
HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes
HCA's Q4 EPS surge 28.8% year over year to $8.01, beating estimates on strong patient volumes and higher revenue per equivalent admission.
Zacks·9d ago
News Placeholder
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts
Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) has been given an average recommendation of "Buy" by the fifteen brokerages that are currently covering the company, Marketbeat Ratings...
MarketBeat·12d ago
News Placeholder
Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO
Emerald Mutual Fund Advisers Trust decreased its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.3% during the third quarter, according to its most recent 13F filing...
MarketBeat·14d ago
News Placeholder
FY2025 Earnings Estimate for SLNO Issued By HC Wainwright
Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a report...
MarketBeat·14d ago
News Placeholder
Emerald Advisers LLC Trims Position in Soleno Therapeutics, Inc. $SLNO
Emerald Advisers LLC lessened its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 6.7% in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·15d ago
<
1
2
...
>

Latest SLNO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.